Meeting
2022 ASCO Annual Meeting
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
Authors
Brian Andrew Van Tine
Washington University in Saint Louis, St. Louis, MO
Brian Andrew Van Tine , Joleen M. Hubbard , Monica M. Mita , Minal A. Barve , Erika P. Hamilton , Andrew J. Brenner , Frances Valdes , Daniel H. Ahn , Jason S. Starr , Joshua Pelham , Thomas Strack , Amy Yuet , Diana Yurewicz , Taunya J. Smith , Andres Machado , William Jeffery Edenfield , Aki Morikawa , Meena Okera , Nihal E. Abdulla , Zev A. Wainberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04029922
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2583)
DOI
10.1200/JCO.2022.40.16_suppl.2583
Abstract #
2583
Poster Bd #
238
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
First Author: Joleen M. Hubbard
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz
Poster
2022 ASCO Annual Meeting
![Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).](https://d201v5jt9ylckg.cloudfront.net/288/14358/211355/211355_A1369_poster_pv.jpg)
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
First Author: Fabrice Andre
Poster
2022 ASCO Annual Meeting
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.
First Author: Jifang Gong